Daxor (NASDAQ:DXR) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst Says

Daxor (NASDAQ:DXR) had its price target boosted by stock analysts at Ascendiant Capital Markets from $24.75 to $25.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Ascendiant Capital Markets’ price objective points to a potential upside of 210.56% from the company’s previous close.

Daxor Stock Performance

Daxor stock opened at $8.05 on Monday. The business has a 50-day simple moving average of $7.79 and a two-hundred day simple moving average of $8.48. Daxor has a 52-week low of $6.55 and a 52-week high of $10.00.

Insider Buying and Selling at Daxor

In related news, CEO Michael Richard Feldschuh acquired 3,360 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was bought at an average cost of $7.68 per share, for a total transaction of $25,804.80. Following the purchase, the chief executive officer now owns 210,852 shares in the company, valued at $1,619,343.36. The trade was a 1.62 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 59.00% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Daxor stock. Keyes Stange & Wooten Wealth Management LLC lifted its stake in shares of Daxor Co. (NASDAQ:DXR) by 34.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,612 shares of the company’s stock after acquiring an additional 3,771 shares during the quarter. Keyes Stange & Wooten Wealth Management LLC owned approximately 0.30% of Daxor worth $126,000 at the end of the most recent reporting period. 1.34% of the stock is currently owned by institutional investors.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.